Latest Industry Insights
Large-Scale Bioproduction of Adherent Cells To Support Advanced Therapy Workflows
In recent years, a number of new cell and gene therapies have been developed to treat a variety of indications, including cancer and inherited retinal dystrophies. While these therapies have proven to be beneficial to patients, their scalability and manufacturability are two enduring challenges. Technology Networks spoke to Tara St.Amand, PhD, MBA, director of business technology, bioprocess at Corning to learn more about the key challenges faced when scaling up the manufacturing of cell products.
Brooks Automation To Unify Services Under Azenta Life Sciences
Technology Networks spoke to Linda De Jesus, senior vice president and chief commercial officer at Azenta Life Sciences to find out more about the announcement and how this will help drive innovation with greater speed and accuracy.
High-Quality Chemical Detection Where It Is Needed Most
To find out more about HPIMS, Technology Networks spoke with Dr. Ching Wu, founder and chief executive officer at Excellims and a pioneer of HPIMS. In this interview, Dr. Wu talks about the advantages that the technique can offer in applications ranging from pharma PAT to clinical diagnostics, and discusses how Excellims is increasing accessibility to the technology.
Unlocking the Power of Cancer Databases
An interview with LARVOL’s Sabrina Bellisario and Dr. Mark Gramling helps provide insights into the importance of precision medicine databases and how LARVOL is providing access to the information pharma and biotech companies need as they develop cancer treatments.
Simulator Technology Can Predict Optimal Vaccine Dosing
Certara is developing biosimulation and tech-enabled approaches to help scientists answer key questions at various stages of the development pipeline, serving to inform and accelerate the path to regulatory approval. One such approach, the company’s Vaccine Simulator™, can be leveraged across different therapeutic areas to determine optimal vaccine dosing and dosing regimens for different patient cohorts.
Making Bioassay Data Easier To Retrieve and Share
Technology Networks had the pleasure of speaking with Dr. Vladimir Makarov, project manager of the Pistoia Alliance Artificial Intelligence and Machine Learning Centre of Excellence, to learn more about the DataFAIRy project, its aims and importance.
Humanized Mice: Generation, Advantages and Applications
Technology Networks recently spoke with Dr. Marvin Ouyang, Cyagen’s executive vice president and chief scientific officer, to learn more about humanized mice and the applications they can benefit. In this interview Dr. Ouyang also explains how humanized mice can be generated and highlights some of Cyagen’s capabilities in this area.
Bringing New Analytical Capabilities to Researchers
As part of efforts to meet the increasing analytical demands of researchers, SCIEX recently announced the launch of the ZenoTOF 7600 system. To learn more about the technology behind the platform and some of the applications that it could benefit, Technology Networks spoke to Joe Fox, president of SCIEX.
A No-Code Cloud Platform for Life Science Research
Technology Networks spoke to Guy Levy-Yurista, CEO of Synthace to find out how the new cloud-based solution can support life science research.
Developing Thermostable Vaccines To Improve Accessibility Worldwide
We spoke to Ozgur Tuncer, chief executive officer of Stablepharma to find out more about the company’s thermo-stabilization technology called StablevaX™ and how it is being used as a complementary technology for COVID-19 vaccines. He also highlights the impact “fridge-free” vaccines could have more generally.